Fluorescently Labeled Antibody Reagent

Shenzhen Wellgrow Biotech Co.,Ltd.

Shenzhen, Guangdong, China

Shenzhen Wellgrow Technology Ltd. is an innovative high-tech enterprise founded based on the National Overseas High-Level Talent Program, specializing in the research, development and industrialization of IVD instruments and reagents. It includes three subsidiaries: Shenzhen Wellgrow Biotechnology Ltd., Beijing Wellgrow Medical Technology Ltd. and Hunan Wellgrow Biotechnology Ltd. As a production base, Shenzhen Wellgrow Biotechnology Ltd. is located in the Shenzhen Biomedical Innovation Industrial Park, the core of the Shenzhen National Bio-Industrial Base. The company's production site is nearly 4,000 m2, including about 400 m2 of Class 100,000 and Class 10,000 ultra-clean factories for the production of IVD reagents, and about 2,400 m2 of workshops for the production of medical equipment. As a R D base, Beijing Wellgrow Medical Technology Ltd., Ltd. is located in the Beijing Life Valley Industrial Base, a national innovation base for biotechnology and new pharmaceutical high-tech industries. The company covers an area of nearly 5,000 m2, including biological laboratories for the development of monoclonal antibodies and encoded microspheres, as well as optical and mechanical laboratories. The core members of the R D team are all from China. Since its establishment, the company has won the Top 300 companies with the most investment value in 2018 (Top 300 Emerging List in Venture50), the 3rd place in the 2019 China Medical Device Innovation and Entrepreneurship Competition, and the 6th place in the finals of the 2020 Smart Cup Frontier Technology Challenge, named TOP5 Enterprises with the Most Investment Value in the biomedical group of the China Association for Science and Technology's Innovation and Venture Capital Conference 2020 in 2020, granted with the winning project award in the 1st National Disruptive Technology Innovation Competition in the Biotechnology Field of the Ministry of Science and Technology in 2021, and honors such as Venture50 Top 50 Healthcare Companies with the Most Investment Value in 2022.